Vancouver, Canada – December 8, 2022 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical trial, for novel anti-aging compound TFC-1326, started on December 5th, 2022.
The trial, which will take place in Paris, is designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles. The formulation is a cream base with TFC-1326 at a concentration of 1% and no other active ingredients.
The trial design was done with the assistance of a leading organization in commercial aesthetics. It will consist of 20 participants, aged 40-65 with specific signs of aging. Participants will begin in weeks 1 through 3 as a rolling start and continue for a 12-week period using the product twice daily. Ten parameters will be measured using advanced technology.
So I'm pretty sure the trial is over and they'll have had about a month to compile and review the results. So Howard....where's the news release? Could you throw a pet contract in there too for good measure? Where does this go if the trial results are just meh?! Has Beiber been interviewing new CEO's? Throw an update or some kind of tidbit out there - wayyyy overdue!